A group of researchers from the South Korean company Hyundai Bioscience, together with CNPHARM, has reached a significant breakthrough in creating a medication from a coronavirus disease (COVID-19) for oral administration, the press service of the company reported.
The press service of the South Korean company Hyundai Bioscience reported that during the experiments on laboratory rats, the drug based on niclozamide under the working title CP-COV03 showed very high efficiency against coronavirus. After receiving one dose, the maximum concentration of the active substance in the blood of animals for 24 hours by 50% exceeded the level required to suppress the virus, transfers the Russian edition “View”.
The main difficulty in creating the medication was that the niclozamide is poorly absorbed by the body and is rapidly excreted from the blood, but the South Korean scientist managed to solve these problems. The company believes that the success of CP-COV03 will be able to “completely change the rules of the game against COVID-19.”
Hyundai Bioscience is ready to start clinical trials of a new medicine, as well as launch the licensing process and start cooperation with large international pharmaceutical companies.